What is the first line treatment for bullous pemphigoid?

Bullous pemphigoid is an autoimmune blistering disorder characterized by the formation of tense bullae, primarily affecting elderly patients. The first line treatment for this condition focuses on controlling the inflammatory response and alleviating symptoms.

High potency topical glucocorticoids, such as clobetasol or halobetasol, are often used as the initial treatment option because they are effective in decreasing inflammation and reducing the formation of new blisters. These potent corticosteroids work locally to target the area involved, minimizing systemic side effects while still providing relief for the patient.

In addition to their anti-inflammatory properties, these medications can help manage itching and promote healing of the affected skin, leading to an improved quality of life for patients with bullous pemphigoid. While oral corticosteroids and other therapies have their place in the treatment regimen for more severe or widespread cases, they are typically not the first-line choice due to their potential for systemic side effects and complications. Thus, high potency topical glucocorticoids serve as the preferred initial approach in managing bullous pemphigoid.